Eli Lilly, the manufacturer of the GLP-1 / GIP agonist tirzepatide (Mounjaro, Zepbound) has announced the development of bimagrumab (LY3985863), an injected monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding
Their ease of use and ability to act systemically make them a convenient option for research and therapeutic purposes
These may indicate a medical emergency requiring urgent treatment
Retatrutide builds on everything tirzepatide does and adds the glucagon receptor component
Most published studies on topical GHK-Cu for hair have been small, often industry-sponsored, and conducted as cosmetic studies rather than as full pharmaceutical trials
It improves athletic performance, aids in weight management, enhances the well-being of the brain and heart, and more